JP2005538974A - 中枢神経系の病気を治療するドーパミン−ｄ３リガンドとして使用するためのヘテロアレーンカルボキサミド - Google Patents

中枢神経系の病気を治療するドーパミン−ｄ３リガンドとして使用するためのヘテロアレーンカルボキサミド Download PDF

Info

Publication number
JP2005538974A
JP2005538974A JP2004518667A JP2004518667A JP2005538974A JP 2005538974 A JP2005538974 A JP 2005538974A JP 2004518667 A JP2004518667 A JP 2004518667A JP 2004518667 A JP2004518667 A JP 2004518667A JP 2005538974 A JP2005538974 A JP 2005538974A
Authority
JP
Japan
Prior art keywords
alkyl
cyano
halogen
hydrogen
alkynyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004518667A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005538974A5 (https=
Inventor
グマイナー ペーター
ヒュプナー ハラルト
シュロッター カーリン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Pharma GmbH
Original Assignee
Schwarz Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10232020A external-priority patent/DE10232020A1/de
Application filed by Schwarz Pharma AG filed Critical Schwarz Pharma AG
Publication of JP2005538974A publication Critical patent/JP2005538974A/ja
Publication of JP2005538974A5 publication Critical patent/JP2005538974A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F17/00—Metallocenes
    • C07F17/02—Metallocenes of metals of Groups 8, 9 or 10 of the Periodic Table
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D345/00—Heterocyclic compounds containing rings having selenium or tellurium atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Furan Compounds (AREA)
  • Indole Compounds (AREA)
JP2004518667A 2002-07-04 2003-07-02 中枢神経系の病気を治療するドーパミン−ｄ３リガンドとして使用するためのヘテロアレーンカルボキサミド Pending JP2005538974A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10230062 2002-07-04
DE10232020A DE10232020A1 (de) 2002-07-04 2002-07-10 Neurorezeptoraktive Heteroarencarboxamide
PCT/EP2003/007060 WO2004004729A1 (de) 2002-07-04 2003-07-02 Heteroarencarboxamide zur verwendung als dopamin-d3 liganden zur behandlung von zns-erkrankungen

Publications (2)

Publication Number Publication Date
JP2005538974A true JP2005538974A (ja) 2005-12-22
JP2005538974A5 JP2005538974A5 (https=) 2006-04-20

Family

ID=30116602

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004518667A Pending JP2005538974A (ja) 2002-07-04 2003-07-02 中枢神経系の病気を治療するドーパミン−ｄ３リガンドとして使用するためのヘテロアレーンカルボキサミド

Country Status (17)

Country Link
US (1) US20050197343A1 (https=)
EP (1) EP1519726B1 (https=)
JP (1) JP2005538974A (https=)
KR (1) KR20050075281A (https=)
CN (1) CN1665503A (https=)
AT (1) ATE354367T1 (https=)
AU (1) AU2003246356A1 (https=)
CA (1) CA2489396A1 (https=)
DE (1) DE50306588D1 (https=)
DK (1) DK1519726T3 (https=)
ES (1) ES2280799T3 (https=)
IL (1) IL165677A0 (https=)
MX (1) MXPA05000033A (https=)
NO (1) NO20050386L (https=)
PL (1) PL374612A1 (https=)
RU (1) RU2320656C2 (https=)
WO (1) WO2004004729A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE521512C2 (sv) * 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
ES2285233T3 (es) 2002-12-20 2007-11-16 Niconovum Ab Un material en particulas que contiene nicotina y celulosa microcristalina fisicamente y quimicamente estable.
DE102004037445A1 (de) * 2004-08-02 2006-03-16 Schwarz Pharma Ag Carboxamide des Indolizins und seiner Aza- und Diazaderivate
DE102004054634A1 (de) * 2004-11-12 2006-05-18 Schwarz Pharma Ag Azaindolcarboxamide
DE102004063797A1 (de) * 2004-12-30 2006-07-13 Schwarz Pharma Ag Sauerstoffhaltige annelierte Phenylpiperazin- und Phenyldiazepancarboxamide
CA2593266A1 (en) * 2005-01-03 2006-07-13 Universita Degli Studi Di Siena Aryl piperazine derivatives for the treatment of neuropsychiatric disorders
US9402809B2 (en) 2006-03-16 2016-08-02 Niconovum Usa, Inc. Snuff composition
FR2903986A1 (fr) * 2006-07-21 2008-01-25 Pierre Fabre Medicament Sa Nouveaux derives chromenes ou thiochromenes carboxamides, leur procede de preparation et leurs applications en therapeutique
WO2008153573A1 (en) * 2007-06-15 2008-12-18 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services 4-phenylpiperazine derivatives with functionalized linkers as dopamine d3 receptor selective ligands and methods of use
US9227944B2 (en) 2008-10-10 2016-01-05 Institute Of Pharmacology And Toxicology Academy Of Military Science P.L.A. China Dopamine D3 receptor ligands and preparation and medical uses of the same
JP5701213B2 (ja) * 2008-10-10 2015-04-15 インスティチュート オブ ファーマコロジー アンド トキシコロジー アカデミー オブ ミリタリー メディカル サイエンシズ ピー．エル．エー．チャイナ 新規なドーパミンｄ３受容体リガンド、その調製及び使用
FR2949465B1 (fr) * 2009-09-01 2011-08-12 Pf Medicament Derives chromones, leur procede de preparation et leurs applications therapeutiques
US11299476B2 (en) 2016-03-14 2022-04-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dopamine D3 receptor selective antagonists/partial agonists; method of making; and use thereof
SI3429993T1 (sl) 2016-03-14 2021-09-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health, Office Of Technology Transfer Selektivni antagonisti/delni agonisti dopaminskega receptorja D3; postopki izdelave; in uporaba le-teh
EP3849963A1 (en) 2018-09-11 2021-07-21 The United States of America, as Represented By the Secretary, Department of Health and Human Services Dopamine d3 receptor selective antagonists/partial agonists and uses thereof
CN114409621B (zh) * 2022-02-09 2023-09-08 江苏省原子医学研究所 一种靶向多巴胺d3受体的诊疗药物及其应用

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3646047A (en) * 1970-02-02 1972-02-29 American Cyanamid Co Certain benzo(b)thiophene-2-carboxamide derivatives
US3646048A (en) * 1970-02-02 1972-02-29 American Cyanamid Co N-(tert-aminoalkyl)-2-indenecarboxamides
JPS5781464A (en) * 1980-09-12 1982-05-21 Deyufuan Intern Reseerufu Bv Phenylpiperazine derivative and attack inhibitor thereof as effective ingredient
JPH0215059A (ja) * 1988-05-24 1990-01-18 American Home Prod Corp 中枢神経系活性を有するアリールおよびヘテロアリールピペラジニルカルボキシアミド
JPH04321677A (ja) * 1991-01-24 1992-11-11 Fab Espanola De Prod Quimicos I Farmaceut Sa 新規の２−メトキシフェニルピペラジン誘導体
JPH06508378A (ja) * 1992-04-09 1994-09-22 アクチエボラゲツト・アストラ 新規アミドアルキル−およびイミドアルキル−ピペラジン類
JPH10502658A (ja) * 1994-07-15 1998-03-10 ビーエーエスエフ アクチェンゲゼルシャフト ドーパミン−ｄ▲下３▼−配位子としての複素環式化合物の使用
JP2000508310A (ja) * 1996-04-05 2000-07-04 ソシエテ・ド・コンセイユ・ド・ルシエルシエ・エ・ダアツプリカーシヨン・シヤンテイフイツク・（エス．セー．エール．アー．エス） α▲下１▼―交感神経受容体拮抗薬
WO2003028728A1 (en) * 2001-09-28 2003-04-10 Richter Gedeon Vegyészeti Gyár Rt. 4-(4-substituted piperazinyl-1yl)-butylcarboxamides as d3 dopamine subtype selective ligands

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5106849A (en) * 1988-05-24 1992-04-21 American Home Products Corporation Use of aryl- and heteroaryl piperazinyl carboxamides in the treatment of various central nervous system disorders

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3646047A (en) * 1970-02-02 1972-02-29 American Cyanamid Co Certain benzo(b)thiophene-2-carboxamide derivatives
US3646048A (en) * 1970-02-02 1972-02-29 American Cyanamid Co N-(tert-aminoalkyl)-2-indenecarboxamides
JPS5781464A (en) * 1980-09-12 1982-05-21 Deyufuan Intern Reseerufu Bv Phenylpiperazine derivative and attack inhibitor thereof as effective ingredient
JPH0215059A (ja) * 1988-05-24 1990-01-18 American Home Prod Corp 中枢神経系活性を有するアリールおよびヘテロアリールピペラジニルカルボキシアミド
JPH04321677A (ja) * 1991-01-24 1992-11-11 Fab Espanola De Prod Quimicos I Farmaceut Sa 新規の２−メトキシフェニルピペラジン誘導体
JPH06508378A (ja) * 1992-04-09 1994-09-22 アクチエボラゲツト・アストラ 新規アミドアルキル−およびイミドアルキル−ピペラジン類
JPH10502658A (ja) * 1994-07-15 1998-03-10 ビーエーエスエフ アクチェンゲゼルシャフト ドーパミン−ｄ▲下３▼−配位子としての複素環式化合物の使用
JP2000508310A (ja) * 1996-04-05 2000-07-04 ソシエテ・ド・コンセイユ・ド・ルシエルシエ・エ・ダアツプリカーシヨン・シヤンテイフイツク・（エス．セー．エール．アー．エス） α▲下１▼―交感神経受容体拮抗薬
WO2003028728A1 (en) * 2001-09-28 2003-04-10 Richter Gedeon Vegyészeti Gyár Rt. 4-(4-substituted piperazinyl-1yl)-butylcarboxamides as d3 dopamine subtype selective ligands

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ABOU-GHARBIA,M.A. ET AL: "Synthesis and SAR of Adatanserin: Novel Adamantyl Aryl- and Heteroarylpiperazines with Dual Serotoni", JOURNAL OF MEDICINAL CHEMISTRY, vol. 42, no. 25, JPN6009045056, 1999, pages 5077 - 5094, XP000973607, ISSN: 0001408018, DOI: 10.1021/jm9806704 *
MOKROSZ,J.L. ET AL: "Structure-activity relationship studies of CNS agents. Part 26. 4-[2-(Cycloalkanecarboxamido)ethyl]-", ARCHIV DER PHARMAZIE(WEINHEIM, GERMANY), vol. Vol.328, No.11-12, JPN6009045084, 1995, pages 770 - 4, ISSN: 0001408020 *
ORJALES,A. ET AL: "New (2-Methoxyphenyl)piperazine Derivatives as 5-HT1A Receptor Ligands with Reduced α1-Adrenergic A", JOURNAL OF MEDICINAL CHEMISTRY, vol. 38, no. 8, JPN6009045085, 1995, pages 1273 - 7, ISSN: 0001408021 *
ROBARGE,M.J. ET AL: "Design and Synthesis of [(2,3-Dichlorophenyl)piperazin-1- yl]alkylfluorenylcarboxamides as Novel Lig", JOURNAL OF MEDICINAL CHEMISTRY, vol. 44, no. 19, JPN6009045081, 2001, pages 3175 - 3186, XP055084201, ISSN: 0001408017, DOI: 10.1021/jm010146o *
WILSON,A.A. ET AL: "Derivatives of WAY 100635 as potential imaging agents for 5-HT1A receptors: syntheses, radiosynthese", NUCLEAR MEDICINE AND BIOLOGY, vol. 25, no. 8, JPN6009045083, 1998, pages 769 - 776, XP004142586, ISSN: 0001408019, DOI: 10.1016/S0969-8051(98)00020-1 *

Also Published As

Publication number Publication date
KR20050075281A (ko) 2005-07-20
AU2003246356A1 (en) 2004-01-23
US20050197343A1 (en) 2005-09-08
WO2004004729A1 (de) 2004-01-15
MXPA05000033A (es) 2005-04-08
ES2280799T3 (es) 2007-09-16
ATE354367T1 (de) 2007-03-15
RU2320656C2 (ru) 2008-03-27
CN1665503A (zh) 2005-09-07
PL374612A1 (en) 2005-10-31
EP1519726B1 (de) 2007-02-21
EP1519726A1 (de) 2005-04-06
CA2489396A1 (en) 2004-01-15
NO20050386L (no) 2005-01-25
IL165677A0 (en) 2006-01-15
RU2004139041A (ru) 2005-07-20
DK1519726T3 (da) 2007-06-04
HK1074579A1 (en) 2005-11-18
DE50306588D1 (de) 2007-04-05

Similar Documents

Publication Publication Date Title
JP2005538974A (ja) 中枢神経系の病気を治療するドーパミン−ｄ３リガンドとして使用するためのヘテロアレーンカルボキサミド
CN1189170C (zh) 噻吩基唑基烷氧基乙胺,它们的制备以及它们作为药物的应用
SK2492002A3 (en) Phenylpiperazine derivatives, process for their preparation and pharmaceutical composition comprising the same
JP2008519797A (ja) アザインドールカルボキシアミド類
JP2019537624A (ja) 化合物、化合物を得るための方法、医薬組成物、化合物の使用、ならびに精神医学的障害および／または睡眠障害を治療するための方法
AU2023395880A1 (en) Crystalline melanocortin subtype-2 receptor (mc2r) antagonist
JPH0225481A (ja) ２―［（４―ピペリジニル）メチル］―１，２，３，４―テトラヒドロイソキノリン誘導体、その製造方法およびその治療への適用
CN1043574C (zh) 具有中枢神经系统活性的杂环胺
CA2178302C (fr) Nouveaux derives de l'indole, de l'indazole et du benzisoxazole,leur pr ocede de preparation et les compositions pharmaceutiques qui les contiennent
JP2008530039A (ja) トランス−１−（（１ｒ，３ｓ）−６−クロロ−３−フェニルインダン−１−イル）−３，３−ジメチルピペラジンの酒石酸塩およびリンゴ酸塩
WO2008080290A1 (en) Selective m4 receptor antagonist and its medical use
JP5055135B2 (ja) トランス−１−（（１ｒ，３ｓ）−６−クロロ−３−フェニルインダン−１−イル）−３，３−ジメチルピペラジンの結晶質塩基
CN102216260A (zh) 氨基酸衍生物
KR20080046205A (ko) 프로드럭으로서 피페라진 및 피페리딘 유도체의 ｎ-산화물
EP0929550A1 (fr) DERIVES DE $i(N)-(BENZOTHIAZOL-2-YL)PIPERIDINE-1-ETHANAMINE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
JP2009545555A (ja) 置換インダニルスルホンアミド化合物、それらの調製、および薬剤としての使用
WO2010040315A1 (zh) 1-丁基-2-羟基芳烷哌嗪衍生物及作为抗抑郁剂的应用
WO2023098612A1 (zh) 二甲基亚磺酰亚胺衍生物的盐型及晶型
JP3902751B2 (ja) ２−（４−アルキル−１−ピペラジニル）−ベンズアルデヒドおよびベンジリデニル化合物の製造方法
JPH0558633B2 (https=)
EP1683790A1 (en) 3,4-dihydro-2-naphthamide derivatives as selective dopamine D3 ligands
CN114105753B (zh) 漆黄素衍生物及其在制备抗炎药物中的应用
SK20795A3 (en) 1-/2-(1h-indene-3-yl) ethyl/-4-(naphthyl) piperazine derivatives, method of their preparation and pharmaceutical compositions containing these derivatives
CN112851643B (zh) 嘧啶苯甲酰胺化合物的盐酸盐及其用途
CN101560178A (zh) 一种多取代吲哚啉类化合物、其制备方法及医药用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060223

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060223

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090904

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100219